| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Pseudolaric Acid A targets multiple cellular pathways. It induces apoptosis, disrupts microtubule formation, and inhibits cell proliferation in various tumor cell lines. It has antifungal activity, suggesting targets in fungal cells. It has anti-inflammatory and immunomodulatory activities. It exhibits specific antiangiogenic properties. Its mechanism of action involves disruption of microtubule formation, leading to cell cycle arrest and apoptosis.
|
|---|---|
| ln Vitro |
In vitro, Pseudolaric Acid A exhibits potent antifungal, cytotoxic, and antifertilization activities. It induces apoptosis, disrupts microtubule formation, and inhibits cell proliferation in various tumor cell lines. It has anti-inflammatory and immunomodulatory activities. It exhibits specific antiangiogenic properties. Quantitative IC50 values for its cytotoxic effects against specific cancer cell lines are not detailed in the publicly available sources.
|
| ln Vivo |
In vivo activity data for Pseudolaric Acid A is limited in publicly available literature. As a compound with potent antifungal, anticancer, anti-inflammatory, and immunomodulatory activities in vitro, it is hypothesized to exhibit similar effects in animal models. Its specific antiangiogenic properties suggest potential for in vivo studies on angiogenesis. However, detailed in vivo efficacy studies, including pharmacokinetic and pharmacodynamic parameters, have not been extensively reported. Further research is needed to fully characterize its in vivo activity and therapeutic potential.
|
| Enzyme Assay |
For in vitro cell-free assays, the antifungal activity of Pseudolaric Acid A can be assessed using standard antifungal susceptibility testing against various fungal strains. Its cytotoxic activity can be assessed using enzyme inhibition assays targeting cancer-related pathways. Its antiangiogenic activity can be studied using in vitro angiogenesis assays such as endothelial cell tube formation assays. Its ability to disrupt microtubule formation can be assessed using tubulin polymerization assays.
|
| Cell Assay |
For in vitro cellular assays, the cytotoxic activity of Pseudolaric Acid A is assessed in various tumor cell lines. Cells are treated with various concentrations of the compound, and cell viability is measured using MTT or SRB assays. Apoptosis is assessed by flow cytometry (Annexin V/PI staining) and caspase activity assays. Microtubule disruption is assessed by immunofluorescence staining of tubulin. Its antiangiogenic activity is assessed using endothelial cell tube formation assays.
|
| Animal Protocol |
For in vivo studies, Pseudolaric Acid A could be administered orally or intraperitoneally in animal models of cancer, fungal infection, or inflammation. In cancer models, endpoints include tumor volume measurement, angiogenesis assessment, and survival analysis. In antifungal studies, endpoints include reduction in fungal load and survival. In inflammation models, endpoints include inflammatory biomarker analysis and tissue histopathology.
|
| ADME/Pharmacokinetics |
Pseudolaric Acid A (CAS 82508-32-5) has a molecular formula of C22H28O6 and a molecular weight of 388.45 g/mol. IUPAC name: (2E,4E)-5-[(3R,4S,4aS,9aR)-4a-(Acetyloxy)-3,4,4a,5,6,9-hexahydro-3,7-dimethyl-1-oxo-1H-4,9a-ethanocyclohepta[c]pyran-3-yl]-2-methyl-2,4-pentadienoic acid. Appearance: typically a powder. Solubility: soluble in DMSO and other organic solvents. Storage: typical for diterpenoids (desiccated, protected from light, -20°C). Purity: typically >98% for research use.
|
| Toxicity/Toxicokinetics |
No detailed toxicity data is publicly available. As a natural diterpenoid from Pseudolarix kaempferi, its safety profile would need to be established through standard toxicological studies. In vitro cytotoxicity assays in various cell lines are typically performed alongside efficacy studies to confirm that observed effects are not due to a general reduction in cell viability.
|
| References |
|
| Additional Infomation |
Reports indicate that pseudolarix acid A has been found in Pseudolarix amabilis and Larix kaempferi, and relevant data are available for reference.
Pseudolaric Acid A is a research-grade compound and is not approved for therapeutic use. It serves primarily as a pharmacological tool for studying anticancer, antifungal, and anti-inflammatory mechanisms. Its mechanism of action involves induction of apoptosis, disruption of microtubule formation, and inhibition of cell proliferation. It has specific antiangiogenic properties. No clinical trials have been reported. |
| Molecular Formula |
C22H28O6
|
|---|---|
| Molecular Weight |
388.45412
|
| Exact Mass |
388.188
|
| CAS # |
82508-32-5
|
| PubChem CID |
6436278
|
| Appearance |
White to off-white solid powder
|
| Density |
1.23
|
| Boiling Point |
571.5±50.0 °C at 760 mmHg
|
| Melting Point |
206-207 ºC
|
| Flash Point |
196.6±23.6 °C
|
| Vapour Pressure |
0.0±3.4 mmHg at 25°C
|
| Index of Refraction |
1.563
|
| LogP |
3.49
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
806
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
CC1=CC[C@]23CC[C@H]([C@]2(CC1)OC(=O)C)[C@@](OC3=O)(C)/C=C/C=C(\C)/C(=O)O
|
| InChi Key |
GOHMRMDXUXWCDQ-MPVZDDSSSA-N
|
| InChi Code |
InChI=1S/C22H28O6/c1-14-7-11-21-12-9-17(22(21,13-8-14)27-16(3)23)20(4,28-19(21)26)10-5-6-15(2)18(24)25/h5-7,10,17H,8-9,11-13H2,1-4H3,(H,24,25)/b10-5+,15-6+/t17-,20+,21+,22-/m0/s1
|
| Chemical Name |
(2E,4E)-5-[(1R,7S,8S,9R)-7-acetyloxy-4,9-dimethyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~257.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5743 mL | 12.8717 mL | 25.7433 mL | |
| 5 mM | 0.5149 mL | 2.5743 mL | 5.1487 mL | |
| 10 mM | 0.2574 mL | 1.2872 mL | 2.5743 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
